· Published by Health Canada · Official notice
This is duplicated text of a letter from Baxter Corporation.
Contact the company for a copy of any references, attachments or enclosures.
August 15, 2011
Dear Health Care Professional,
Subject: Association of mesna (Uromitexan), multi-dose vials with fatal gasping syndrome in neonates and infants
This letter is being sent out following consultation with Health Canada regarding mesna (Uromitexan) multi-dose vials which was recently approved in Canada. Baxter Corporation is issuing this letter to ensure that you have the most recent information available when considering mesna (Uromitexan) multi-dose vials as a treatment option in urinary tract toxicity.
Mesna (Uromitexan), multi-dose vials is indicated for the reduction and prevention of urinary tract toxicity (hemorrhagic cystitis) of oxazaphosphorines (such as Ifosfamide, Glufosfamide and Cyclophosphamide).
Baxter Corporation advises you that the new multi-dose vials of mesna (Uromitexan) contain benzyl alcohol. Mesna (Uromitexan) is only indicated for use in adults and children 13 years and older. The preservative benzyl alcohol can cause serious or fatal reactions in neonates and infants, and can also cause adverse events in older pediatric patients. Cases of neonatal 'gasping syndrome' have been reported in association with the intravenous administration of products containing benzyl alcohol as preservative. Neonatal gasping syndrome is characterized by severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low-birth weight infants.
The Product Monograph for mesna (Uromitexan) multi-dose vials contains a warning box about the potential risk of fatality in neonates and infants due to the benzyl alcohol content of the multi-dose vials. In addition, the Precautions-Use in children section has been updated to specify this risk.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of fatal gasping syndrome or other fatal, serious or unexpected adverse reactions in patients receiving UROMITEXAN should be reported to Baxter Corporation or Health Canada.
Baxter Corporation,
Mississauga, Ontario
1-888-719-9955
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
To change your mailing address or fax number, contact the Market Authorization Holder (Industry).
Sincerely,
original signed by
Adel Gehchan, MD
Director, Medical and Clinical Affairs
Baxter Corporation